Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
— Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business — Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch — Acquires Aculys Pharma Including Rights to Pitolisant in Japan and Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region — Returns More Than $920 […]